City
Epaper

India's pharma exports clock double-digit growth amid surging demand in US, UK

By IANS | Updated: June 18, 2024 13:00 IST

New Delhi, June 18 India’s pharmaceutical exports continue to register double-digit growth, reflecting the strong demand for the ...

Open in App

New Delhi, June 18 India’s pharmaceutical exports continue to register double-digit growth, reflecting the strong demand for the country’s affordable generic medicines in global markets led by the USA and UK.

India’s pharma exports grew by 10.45 per cent in May this year to touch the $2.3 billion mark compared with the $2.08 billion in the same month of the previous financial year.

“It is moving in a positive way and we are optimistic of sustaining growth of not less than 10 per cent,” Director General, Pharmaceuticals Export Promotion Council of India, Ravi Uday Bhaskar said on the quick estimate numbers released last week by the Centre.

India is now the world's third-largest drugmaker by volume amid the growing demand for the country’s pharmaceutical products in export markets.

The US is a key market, which accounts for about 30 per cent of India's annual pharma exports after a nearly 16 per cent increase in fiscal 2024, according to Pharmexcil.

The country's drug shortages as well as the increased use of drugs for lifestyle diseases such as diabetes, hypertension and depression is expected to fuel the demand for India's affordably priced drugs, according to Bhaskar.

According to a report by India Ratings and Research, Indian drugmakers will sustain their revenue improvement in 2024-2025 due to drug shortages in the United States. India is a hub of bulk generic drug manufacturing and drugmakers including Dr Reddy's, Cipla, Sun Pharma derive a significant share of revenue from both the US and Europe.

The world's largest drug market is facing decade-high drug shortages, India Ratings said in a note citing data from with Utah Drug Information Service.

There is an active shortage of 233 drugs across 22 therapeutic categories as of April, led mainly by discontinuing production of some drugs, rising demand and delays in shipments, it said, also citing data from the US Food and Drug Administration.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

EntertainmentSS Rajamouli's 'Baahubali' to be re-released

MumbaiMumbai Accident: 18-Year-Old Girls Die After Scooter Skids While Overtaking Truck in C.P. Tank Circle

NationalIndia's changemakers speak: Padma awardees reflect on recognition and responsibility

Other Sports‘Remember the name’: Social media bows down to Survanshi’s debut ton

CricketInjured Rahul Dravid Stands Up from Wheelchair to Applaud 14-Year-Old Vaibhav Suryavanshi After Record 35-Ball Century in RR vs GT IPL 2025 Match (VIDEO)

Business Realted Stories

BusinessGovt targets 100 GW of nuclear power capacity by 2047 to boost energy security

BusinessAdani Green surpasses $1 bn in EBITDA in FY25, RE capacity up 30 pc to 14.2 GW

BusinessPM Modi to address YUGM innovation conclave tomorrow

BusinessNippon Life India reports nearly 9 pc drop in net profit for Q4

BusinessIndustry veteran Pawan Kumar Goenka conferred with Padma Shri